Lu Peng sold $3.5M of PHVS

Lu Peng (President) sold 100,000 shares of Pharvaris N.V. (PHVS) at $35.00 ($3.50M total) on 2026-09-17.

Original reporting
SEC EDGAR · Lu Peng
Published Sep 21, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which can be interpreted as a negative signal by the market.

02

Market read

Insider sale is a primary disclosure for a micro‑cap biotech, offering modest trading relevance.

03

What to watch

Potential tax planning or diversification needs of the insider.

Relevance 6/10Novelty 5/10Timing: filed 2026-09-21

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

President Lu Peng sold 100,000 shares for $3.5M, reducing his stake to 64,953 shares.

Expected impact

Possible modest downside of 2-4% over the next few days.

Evidence & confidence

The sale size is material for a micro‑cap biotech and the insider is a top executive; markets often react negatively to such disposals.

Market effects

May weigh on other small‑cap biotech stocks as investors watch insider activity.

Limited to US biotech sector; no broader regional effect.

Minimal global impact.

Counterpoint

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Lu Peng

    President of Pharvaris N.V., insider selling 100,000 shares.

  • Pharvaris N.V.

    Biotech firm listed on Nasdaq under ticker PHVS.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.